Co-trimoxazole (Trimethoprim + Sulfamethoxazole)
Brand names: Septrin
Co-trimoxazole (trimethoprim with sulfamethoxazole) is used for specific infections, notably Pneumocystis jirovecii pneumonia (treatment and prophylaxis), and for some urinary, respiratory and other infections.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The two components block sequential steps in bacterial folate synthesis, producing a synergistic effect.
Prescribing in practice
- It carries sulfonamide risks — serious skin reactions (including Stevens-Johnson syndrome) — and can cause hyperkalaemia and bone-marrow suppression.
- Avoid or use great caution with methotrexate (additive folate antagonism and marrow toxicity) and with other potassium-raising or marrow-suppressing drugs.
- Reduce the dose in renal impairment and ensure good hydration; it is usually reserved for specific indications.
Monitoring
For longer courses monitor FBC, renal function and potassium, and review for rash.
Counselling the patient
- Report any rash promptly, or a sore throat or fever.
- Drink plenty of fluids.
- Tell your clinician about other medicines, especially methotrexate.
Evidence & guidelines
First-line for Pneumocystis pneumonia treatment and prophylaxis, and used selectively for other infections per local guidance.
Reference: BHIVA HIV Guidelines 2023; NICE NG112 (UTI); NICE HIV Management Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023